Please wait while the formulary information is being retrieved.
ADZYNMA (ADAMTS13, recombinant-krhn)
- congenital thrombotic thrombocytopenic purpura
1,500 unit intravenous kit
- Dosage information is not available
500 unit intravenous kit
- Dosage information is not available
- None
Contraindicated
- None
Severe
Moderate
- None
- None
Contraindicated
- None
Severe
Moderate
- No disease contraindications
ADZYNMA (ADAMTS13, recombinant-krhn)
- congenital thrombotic thrombocytopenic purpura
- None
- Acute abdominal pain
- Diarrhea
- Dizziness
- Headache disorder
- Migraine
- Nausea
- Upper respiratory infection
- Vomiting
More Frequent
Severe
Less Severe
- Anaphylaxis
- None
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- None
Less Severe
- None
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
ADAMTS13, recombinant-krhn
Safety and effectiveness not established in pediatrics age < 2 years.
- 1 Day – 2 Years
- Safety and effectiveness not established in pediatrics age < 2 years.
Adamts13, Recombinant-krhn
- Severity Level:
2
- Additional Notes: Insuff human data avail; consider maternal tx benefit vs potential neonatal risk
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
Adamts13, Recombinant-krhn
Insufficient human data available
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Unknown | Not known; no or inclusive data | Insufficient human data available |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- None
| Congenital thrombotic thrombocytopenic purpura | |
| D69.42 | Congenital and hereditary thrombocytopenia purpura |
| 0-9 | A-Z |
|---|---|
| D69.42 | Congenital and hereditary thrombocytopenia purpura |
Formulary Reference Tool